Development and validation of a respiratory syncytial virus multiplex immunoassay
Authors:
- Patrick MarsallPMPatrick Marsall
- RESPINOW study consortiumRCRESPINOW study consortium
Preprint
Abstract
Respiratory syncytial virus (RSV) is one of the leading causes of severe respiratory disease in infants and adults. RSV exists as two subtypes A and B, which co-circulate throughout the season, although one will usually become dominant. While vaccines and monoclonal therapeutic antibodies either are or will shortly become available, correlates of protection remain unclear. For this purpose, we developed an RSV multiplex immunoassay that analyses antibody titers towards the post-F, Nucleoprotein, and a diverse mix of G proteins. Technical and clinical validation showed outstanding performance, while methodological developments enabled identification of the subtype of previous infections through use of the diverse G proteins for approximately 50% of samples. As a proof of concept to show the suitability of the assay in serosurveillance studies, we then evaluated titer decay and age- dependent antibody responses within population cohorts. Overall, the developed assay shows robust performance, is scalable, provides additional information on infection subtype, and is therefore ideally suited to be used in future population cohort studies. Importance: Although respiratory syncytial virus (RSV) is endemic and re-infections are common and harmless to the majority of the population, it is a leading cause of hospitalization in young children, the elderly, or immunocompromised individuals. A better characterization of RSV immunology and spreading dynamics is thus critical for preparedness, especially when interventions aiming to mitigate other diseases (e.g., COVID-19) disturb its endemic cycles. This requires high-throughput information-dense assays. We therefore developed a bead-based multiplex immunoassay that allows measurements of antibodies against multiple RSV antigens simultaneously. We identified antibodies which were strong indicators of previous infection, while others allowed identification of the subtype of the previous infection. The assay itself was shown to be robust and scalable, making it ideal for to keep track of the temporal variation RSV immunity profiles within the population.Keywords
All Related Versions
- Published version: Infection, 52 (2), 597.
This publication has 45 references indexed in Scilit:
- Structure and Function of Respiratory Syncytial Virus Surface Glycoproteins2013
- Systematic reference sample generation for multiplexed serological assaysScientific Reports, 2013
- Structure of RSV Fusion Glycoprotein Trimer Bound to a Prefusion-Specific Neutralizing AntibodyScience, 2013
- Respiratory Syncytial Virus—A Comprehensive ReviewClinical Reviews in Allergy & Immunology, 2013
- Prospects for Defined Epitope Vaccines for Respiratory Syncytial VirusFuture Microbiology, 2010
- The Burden of Respiratory Syncytial Virus Infection in Young ChildrenNew England Journal of Medicine, 2009
- Respiratory Syncytial Virus Infection in Elderly and High-Risk AdultsNew England Journal of Medicine, 2005
- Variation in severity of respiratory syncytial virus infections with subtypeThe Journal of Pediatrics, 1990
- The G glycoprotein of human respiratory syncytial viruses of subgroups A and B: extensive sequence divergence between antigenically related proteins.Proceedings of the National Academy of Sciences, 1987
- Characterization of the 10 proteins of human respiratory syncytial virus: Identification of a fourth envelope-associated proteinVirus Research, 1985